Press Releases for CRME

Press Releases
Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
Cardiome Reports Second Quarter Results
Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement
Cardiome to Hold Conference Call
Cardiome Announces Management Transition
Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
Cardiome Achieves Milestone From Collaboration With Merck & Co., Inc.
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
Cardiome Reports First Quarter Results
Merck Announces First-Quarter 2009 Financial Results
AnalystChoice.Com Free Investment Opinion on LKQX, JOSB, CRME and BIIB
Cardiome to Hold Conference Call - PR Newswire
Cardiome to Hold Conference Call - CNW
Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation
Cardiome Reports 2008 Results
Cardiome Discloses Chairman And CEO's Involuntary Share Sale
Cardiome Reports Third Quarter Results
Cardiome Reports Third Quarter Results
Cardiome Announces Filing Of Shelf Registration Statement
Cardiome Provides Regulatory Update
Cardiome Reports Second Quarter Results
Cardiome Reports Second Quarter Results
Cardiome to Release Second Quarter Results and Hold Conference Call
Cardiome to Release Second Quarter Results and Hold Conference Call
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
Cardiome Announces Preferred Share Financing
Cardiome Announces Preferred Share Financing
Cardiome Announces Positive Phase 2b Results For Oral Vernakalant
Cardiome Announces Positive Phase 2b Results For Oral Vernakalant
Cardiome To Hold Conference Call
Cardiome To Hold Conference Call
K I L L K I L L K I L L -- Cardiome Pharma Corp.
TEST - Jay 14 - Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
Cardiome Reports First Quarter Results - Jun 1 2008 4:54PM
Cardiome To Release 2008 First Quarter Results - Jun 1 2008 4:54PM